Resource | Description | Cystic Fibrosis | Controls w/o CF | # of samples/ sections | Start Date | Contact |
---|---|---|---|---|---|---|
Airway and Lung Parenchyma | Tissue from explanted lungs from patients with CF; typically processed within 24 -48 hours post-surgery | 33 | 2009 | Pradeep Singh, MD | ||
Pancreatic sections | Pancreatic autopsy tissue sections from patients with cystic fibrosis, with and without CF related diabetes, and non-CF controls with and without Type II diabetes | 43 | 55 | 3-10 sections/participant, ~300 CF; ~400 non-CF | 2012 | Chuck Frevert, DVM, PhD |
Stool | Stool samples collected longitudinally over 12 month period from infants and young children; refrigerated after collection; frozen at -80 C within 24 – 72 hours | 15 | 13 | 140 | 2011 | Luke Hoffman, MD, PhD |
Expectorated Sputum | Spontaneously expectorated sputum collected longitudinally; refrigerated at 4 C after collection and stored at -80 C within 24 – 48 hours after collection | 45 | 120 | 2011 | Luke Hoffman, MD, PhD | |
Expectorated Sputum | Spontaneously expectorated sputum collected longitudinally; refrigerated at 4 C after collection and stored at -80 C within 24 – 48 hours after collection | 54 | 587 | 2009 | Pradeep Singh, MD |
|
Expectorated Sputum | Spontaneously expectorated sputum collected longitudinally; refrigerated at 4 C after collection and stored at -80 C within 24 – 48 hours after collection | 12 | 41 | 2013 | Pradeep Singh, MD |
|
Microbial DNA preps | Microbial DNA preps available from explanted lungs | 16 | 123 | 2009 | Pradeep Singh, MD Luke Hoffman, MD, PhD |
|
Bacterial Isolates | Bacterial populations isolated from expectorated sputum samples (96 isolates per “population”) | 54 | 406 bacterial populations including 27 from patients with exacerbation; 144 from patients during antibiotic treatment | 2009 | Pradeep Singh, MD |
|
Bacterial isolates | Populations of bacterial isolates cultured from explanted lung tissue of upper, middle and lower lobes and lingula | 13 | 131 populations from 10 lungs | 2009 | Pradeep Singh, MD |
|
Bacterial Isolates | Populations of P. aeruginosa isolates from 8 CF subjects with the G551D genotype prior to (day 0) and after (days 2, 8, 90, 210, 420) receiving ivacaftor | 8 | 41 populations of 96 isolates each from 8 subjects | 2013 | Pradeep Singh, MD |
|
Serum | Samples banked at multiple time points during oral glucose tolerance testing; frozen at -80 C | 11 | 66 | 2014 | Ron Gibson, MD, PhD | |
Airway and Lung Parenchyma | Formalin fixed paraffin embedded (FFPE) tissue sections from lung biopsies, lobectomies and postmortem lungs from patients with CF; subset have lung snap frozen stored at -80C. Age-matched controls | 43 | 25 | Multiple sections per participant. 10 stored frozen | 1975 | Gail Deutsch, MD |
Pancreas | Formalin fixed paraffin embedded (FFPE) tissue sections from autopsies of patients with cystic fibrosis, with and without CF related diabetes, and age-matched non-CF controls; subset have pancreas snap frozen stored at -80C | 20 | 16 | Multiple sections per participant 3 stored frozen | 1975 | Gail Deutsch, MD |
Liver | Formalin fixed paraffin embedded (FFPE) tissue sections from liver biopsies from patients with CF processed within 24 hours post-surgery; subset have liver snap frozen stored at -80C | 15 | TBD | 3-10 sections per participant 12 stored frozen | 2002 | Gail Deutsch, MD |
Bowel resections for meconium ileus | Formalin fixed paraffin embedded (FFPE) tissue sections from bowel resections from patients with CF processed within 24 hours post-surgery | 11 | TBD | Multiple sections per participant | 2002 | Gail Deutsch, MD |
Gastrointestinal biopsies | Formalin fixed paraffin embedded (FFPE) tissue sections from gastrointestinal biopsies from patients with CF processed within 24 hours post-surgery | 47 | TBD | 3-10 sections per participant | 2002 | Gail Deutsch, MD |
Historical Biospecimens | ||||||
Bacterial Isolates | Longitudinal clinical bacterial isolates (P. aeruginosa, S. aureus [MSSA, MRSA, SCV], S maltophilia, Achromobacter spp., B. cepacia complex), cultured from upper and lower respiratory specimens and explanted lung tissue from individual patients cared for at SCH and UWMC. | All isolates from individuals with CF | Over 25,000 clinical isolates | Luke Hoffman, MD, PhD MOAC request form |
||
Bacterial Isolates | Isolates of P. aeruginosa, S. aureus [MSSA, MRSA, SCV], S maltophilia, Achromobacter spp., and B. cepacia complex derived from 14 observational and interventional studies processed in the CFF Center for CF Microbiology at Seattle Children's; specific source studies. | All isolates from individuals with CF | 9500 isolates from 14 clinical trials | Luke Hoffman, MD, PhD MOAC request form |
||
Ordered transposon mutant library of Pseudomonas aeruginosa | Created a near-saturation sequence defined transposon mutant library in which individual mutants are arrayed and can be retrieved for distribution. 'Random' transposon insertion mutants were arrayed and sequenced to define the transposon insertion locations in the genome of P. aeruginosa strain PA01. | 9437 | Steve Salipante Pa Mutant Library |
|||
Serum | Longitudinal serum samples collected pre, during post therapeutic intervention in a multicenter clinical trial in pediatric patients | 66 | 1715 aliquots | Ron Gibson, MD, PhD | ||
Bronchoalveolar lavage (BAL) | BAL collected pre- and post- therapeutic intervention in a multicenter clinical trial in pediatric patients | 44 | 1215 aliquots | Ron Gibson, MD, PhD | ||
Data Repository | ||||||
Research clinical data | Data from 21 Phase 3 multi-center trials involving over 3000 patients; described on the CFRTC website | > 3000 | TDN contact: Sonya Heltshe |